Inclusion Criteria:

- Patients are able to provide written informed consent

- Patients must have CML in CP which is defined by the presence of all of the following
criteria:

- < 15% blasts in peripheral blood (PB) and BM.

- < 30% blasts plus promyelocytes in PB and BM.

- < 20% basophils in the PB.

- ≥ 100 x 109/L platelets.

- No evidence of extramedullary leukemia apart from hepatosplenomegaly

- Ph+ or variants must be demonstrated by BM cytogenetics, FISH or PCR.

- Previously untreated CML in CP, with the exception of hydroxyurea or anagrelide

- Patients must be enrolled in this study within 90 days after the date of first being
diagnosed with CML

- ECOG Performance Status (PS) Score 0 - 1 (see Appendix 2)

- Adequate hepatic function defined as: total bilirubin ≤ 2.0 times the institutional
upper limit of normal (ULN) in absence of Gilbert type unconjugated
hyperbilirubinemia; alanine aminotransferase (ALAT≤ 2.5 times the institutional ULN.

- Adequate renal function defined as serum creatinine ≤ 2 times the institutional ULN.

- Men and women, ages 18 years and older.

- Adequate BM aspiration sample before the start of study treatment (i.e sample is
sufficient for stem cell analysis)

- Potentially fertile women must use an adequate method of contraception to avoid
pregnancy throughout the study.

- Potentially fertile women must have a negative serum or urine pregnancy test

Exclusion Criteria:

- Fertile women who are unwilling or unable to use an acceptable method to avoid
pregnancy for the entire study

- Women who are pregnant or breastfeeding.

- Men with fertile sexual partners who can or will not use an acceptable contraception
method for the entire study

- A serious uncontrolled medical disorder or active infection that would impair the
ability of the subject to receive protocol therapy.

- Known pleural effusion at baseline.

- Uncontrolled or significant cardiovascular disease

- History of significant bleeding disorder unrelated to CML, including:

- Prior chemotherapy for peripheral stem cell mobilization.

- Inadequate BM aspiration sample due to marrow fibrosis or other reasons

- Prior or concurrent malignancy

- Severe psychiatric illness, imprisonment or mental impairment inflicting on ability
to give informed consent

- Abuse of alcohol, prescribed or illicit drugs

- Evidence of digestive dysfunction that would prevent administration of study therapy
by mouth.

- Prohibited Treatments and/or Therapies

- Any prior treatment with interferon

- Any prior treatment with dasatinib

- Any prior treatment with imatinib

- Any other prior systemic treatments, with anti-CML activity [except for
anagrelide, or hydroxyurea (HU)].

- Patients currently taking drugs that are generally accepted to have a risk of causing
Torsades de Pointes as described in Appendix 3.